News archive
Showing 671 results
October 2017
-
Media ReleaseNovartis collaborates with pop icon Cyndi Lauper to release new song in honor of World Psoriasis Day
-
Media ReleaseNovartis drug Promacta® shows long-term disease control for chronic/persistent immune thrombocytopenia (ITP)- Nearly 70% of patients maintained platelet counts of ≥30×10[9]/L without rescue therapy for prolonged periods, reducing the overall risk of bleeding- More than one-third of patients permanently…
-
Media ReleaseNovartis drug Promacta® shows long-term disease control for chronic/persistent immune thrombocytopenia (ITP)
September 2017
-
Media ReleaseAlcon DAILIES® teams up with US Olympians - world-class gymnast Laurie Hernandez and soccer star Tobin Heath - to launch the Invisible Edge campaignConsumer education campaign highlights the important role of vision in giving "everyday" athletes an invisible edge on and off the fieldNew survey uncovers that clear eyesight is more important than…
-
Media ReleaseAlcon DAILIES® teams up with US Olympians - world-class gymnast Laurie Hernandez and soccer star Tobin Heath - to launch the Invisible Edge campaign
-
Media ReleaseNovartis teams up with actress, producer and activist Eva Longoria to launch Kiss This 4 MBC™ to generate research funding and support for the metastatic breast cancer community- Kiss This 4 MBC goes beyond raising awareness of metastatic breast cancer to generate an increase in public support and research funds for the estimated 155,000 people living with this disease in…
-
Media ReleaseNovartis teams up with actress, producer and activist Eva Longoria to launch Kiss This 4 MBC™ to generate research funding and support for the metastatic breast cancer community
-
Media ReleaseNovartis Cosentyx® sets the new benchmark in psoriasis with robust 5-year sustained efficacy and safety Phase III data- Cosentyx® (secukinumab) is the first and only fully human IL-17A antagonist to show sustained skin clearance rates at 5 years in Phase III in psoriasis(1)- Landmark data show that PASI 90 and PASI…
-
Media ReleaseNovartis Cosentyx® sets the new benchmark in psoriasis with robust 5-year sustained efficacy and safety Phase III data
August 2017
-
Media ReleaseMultimedia Assets Now Available: Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah™ (tisagenlecleucel, CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice- First-in-class therapy showed an 83% (52/63) overall remission rate in this patient population with limited treatment options and historically poor outcomes1,2- Novel approach to cancer treatment…
-
Media ReleaseNovartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah™ (tisagenlecleucel, CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice- First-in-class therapy showed an 83% (52/63) overall remission rate in this patient population with limited treatment options and historically poor outcomes1,2- Novel approach to cancer treatment…
-
Media ReleaseMultimedia Assets Now Available: Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah™ (tisagenlecleucel, CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice